BriaCell Therapeutics (TSX-V:BCT) (OTCQB:BCTXF) announced that early Phase 1/2a data suggest its Bria-IMT immunotherapy, combined with the checkpoint inhibitor KEYTRUDA, demonstrated additive or synergistic anti-tumor activity.
The study assessed the drug combination in six advanced breast cancer patients that were previously treated with a median of five prior systemic therapy regimens, such as chemotherapy, with no response.
One patient, who had previously received Bria-IMT monotherapy, experienced a 43% reduction in size of liver metastases. Another patient, who had not previously received Bria-IMT monotherapy but nine prior anti-cancer regimens, achieved stable disease.
“We are impressed with the early data of the combination study, suggesting efficacy and clinical benefits in a heavily-treated, difficult to treat patient population,” Bill Williams, BriaCell’s president and CEO, said in a statement.
Enrollment for BriaCell’s Phase 2a study of Bria-IMT combined with checkpoint inhibitors is ongoing.
